Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)

Overview

In this prospective observational study, the investigators want to document pharmacokinetic/pharmacodynamic (PK/PD) target attainment of frequently used antimicrobials in an adult non critically ill surgery population (abdominal surgery, traumatology and septic orthopedic surgery). Furthermore, the investigators want to identify risk factors for not attaining predefined PK/PD targets. The antibiotics of interest are amoxicillin(-clavulanic acid), flucloxacillin, piperacillin-tazobactam, meropenem and clindamycin.

Full Title of Study: “Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 30, 2018

Detailed Description

In this research proposal, the primary objective is to describe PK parameters (area under the curve (AUC), clearance (Cl), distribution volume (Vd) and half life (T1/2)) for the antibiotics of interest (amoxicillin(-(clavulanic acid), flucloxacillin, piperacillin-tazobactam, meropenem and clindamycin) for this adult non critically ill surgery population. Besides, the investigators want to document pharmacokinetic/pharmacodynamic (PK/PD) target attainment of frequently used ABs in this population and to identify risk factors, for example augmented renal clearance (ARC), for not attaining predefined PK/PD targets.

Interventions

  • Drug: amoxicillin-clavulanic acid
    • During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined. Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² .

Clinical Trial Outcome Measures

Primary Measures

  • The % of time that free concentrations of antimicrobials are above minimal inhibitory concentrations (MIC) or antimicrobial European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints
    • Time Frame: During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.
    • Per antimicrobial of interest, we will determine the % of time that free concentrations are above minimal inhibitory concentrations (MIC) or antimicrobial EUCAST breakpoints

Secondary Measures

  • Area under the plasma concentration versus time curve (AUC)
    • Time Frame: During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.
    • Per antimicrobial of interest, we will determine the pharmacokinetic parameter the area under the plasma concentration versus time curve (AUC).
  • Clearance (Cl)
    • Time Frame: During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.
    • Per antimicrobial of interest, we will determine the pharmacokinetic parameter clearance (Cl).
  • Volume of distribution (Vd)
    • Time Frame: During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.
    • Per antimicrobial of interest, we will determine the pharmacokinetic parameter the volume of distribution (Vd).
  • Half life (T1/2)
    • Time Frame: During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.
    • Per antimicrobial of interest, we will determine the pharmacokinetic parameter the half life (T1/2).
  • Risk factors for target non attainment
    • Time Frame: During 1 dosing interval at steady state. This is at earliest 72h after initialization of the antimicrobial.
    • Multivariate analysis will be performed with target attainment as outcome. This will allow to identify risk factors for target non attainment.

Participating in This Clinical Trial

Inclusion Criteria

Every adult non-critically ill surgery patient admitted at the abdominal, trauma or septic orthopaedic surgery wards from the University Hospitals Leuven treated with multiple doses of one of the antimicrobials of interest (i.e. intravenous (IV) amoxicillin(-clavulanic acid), flucloxacillin, piperacillin-tazobactam, meropenem, oral or IV clindamycin) is eligible for inclusion. Exclusion Criteria:

  • age ≤ 18 years – treatment restrictions corresponding to a Do Not Reanimate code – pregnancy – lactation – renal replacement therapy – planned discharge or surgery in the coming antimicrobial dosing interval making sampling impossible

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Universitaire Ziekenhuizen KU Leuven
  • Provider of Information About this Clinical Study
    • Principal Investigator: peter declercq, Principal investigator – Universitaire Ziekenhuizen KU Leuven
  • Overall Official(s)
    • Peter Declercq, PharmD, Principal Investigator, Universitaire Ziekenhuizen KU Leuven
  • Overall Contact(s)
    • Peter Declercq, PharmD, 003216342340, peter.declercq@uzleuven.be

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.